Iovance Biotherapeutics completes license application submission for advanced melanoma therapy; shares rally

Biotech cancer-treatment developer Iovance Biotherapeutics Inc. IOVA, on Friday said it had completed its rolling biologics license application submission to the U.S. Food and Drug Administration for lifileucel — a therapy intended to combat advanced melanoma in some cases. Interim Chief Executive…#frederickvogt
Source: Reuters: Health - Category: Consumer Health News Source Type: news